Chatterjee Suparna, Dureja Gur Prasad, Kadhe Ganesh, Mane Amey, Phansalkar Abhay A, Sawant Sandesh, Kapatkar Vaibhavi
Department of Pharmacology, IPGMER, Kolkata, India.
Department of Pain Medicine, New Delhi Pain Management Center, New Delhi, India.
Gastroenterology Res. 2015 Aug;8(3-4):216-221. doi: 10.14740/gr658w. Epub 2015 Jul 22.
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most common therapeutic products used for the management of inflammation and pain. However, their use is associated with gastrointestinal (GI), cardiovascular and renal complications. Although prevalence data regarding NSAID-induced complications are available worldwide, but none of the study has assessed the prevalence of GI, cardiac and renal complications in India. This study aimed to assess the point prevalence of GI, cardiac and renal complications associated with the use of NSAIDs in India. The study also aimed to evaluate the association between the risk factors and GI, renal and cardiac complications in patients using NSAIDs.
This prospective, cross-sectional, multi-centric study was conducted in eight medical colleges across India (North, East, West, South and Central India). Data related to GI complications including gastric, duodenal and gastroduodenal erosions/ulcers/gastritis, renal complications including acute and chronic renal failure or cardiac complications including acute coronary syndrome (ACS), acute myocardial infarction (AMI) and cardiac failure, were collected from patients.
The cut-off date for interim data analysis was July 7, 2014. A total of 2,140 patients out of 3,600 were enrolled from eight centers at the time of interim analysis. The NSAID-associated point prevalence of GI complications was 30.08%; cardiac complication was 42.77%; and renal complication was 27.88%.
Results of the present interim analysis show that the prevalence of GI, cardiac and renal complications among patients is high due to exaggerated usage; however, the final analysis would provide the overall prevalence of these complications.
非甾体抗炎药(NSAIDs)是用于治疗炎症和疼痛最常用的治疗产品。然而,其使用与胃肠道(GI)、心血管和肾脏并发症相关。尽管全球范围内都有关于非甾体抗炎药引起并发症的患病率数据,但尚无研究评估印度胃肠道、心脏和肾脏并发症的患病率。本研究旨在评估印度使用非甾体抗炎药相关的胃肠道、心脏和肾脏并发症的时点患病率。该研究还旨在评估使用非甾体抗炎药患者的危险因素与胃肠道、肾脏和心脏并发症之间的关联。
这项前瞻性、横断面、多中心研究在印度各地的八所医学院(印度北部、东部、西部、南部和中部)进行。收集了患者与胃肠道并发症相关的数据,包括胃、十二指肠和胃十二指肠糜烂/溃疡/胃炎,肾脏并发症,包括急性和慢性肾衰竭,或心脏并发症,包括急性冠状动脉综合征(ACS)、急性心肌梗死(AMI)和心力衰竭。
中期数据分析的截止日期为2014年7月7日。在中期分析时,从八个中心共纳入了3600名患者中的2140名。非甾体抗炎药相关的胃肠道并发症时点患病率为30.08%;心脏并发症为42.77%;肾脏并发症为27.88%。
本次中期分析结果表明,由于使用过度,患者中胃肠道、心脏和肾脏并发症的患病率较高;然而,最终分析将提供这些并发症的总体患病率。